Gilead Sciences Inc

Gilead discovers, develops, and commercializes medicines for serious diseases where treatment options are limited. Their core business focuses on HIV treatments like Biktarvy and Descovy, hepatitis medications including Epclusa and Vemlidy, and cancer therapies such as Trodelvy and Yescarta. The company also produces AmBisome for fungal infections and Veklury for COVID-19, while actively developing new immunotherapies through partnerships with other biotech firms.

Gilead Sciences is a major biopharmaceutical company that develops and sells medicines for HIV, hepatitis, cancer, and other serious diseases, generating $29.4 billion in annual revenue [Yahoo Finance]. The company recently reported better-than-expected first-quarter 2026 earnings driven by strong HIV drug sales, particularly Biktarvy, though management raised guidance cautiously due to acquisition-related costs [Yahoo Finance]. Gilead maintains solid financial health with strong margins and cash flow, while recent insider selling and strategic debt issuance signal ongoing business evolution [SEC Form 4] [Yahoo Finance].

Gilead is financially healthy with strong profitability, robust cash generation, and manageable debt levels.